KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Shares Outstanding (Weighted Average) (2019 - 2025)

Ginkgo Bioworks Holdings (DNA) has disclosed Shares Outstanding (Weighted Average) for 5 consecutive years, with $48.8 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Shares Outstanding (Weighted Average) fell 96.99% year-over-year to $48.8 million, compared with a TTM value of $48.8 million through Sep 2023, down 96.99%, and an annual FY2022 reading of $42.0 million, down 96.91% over the prior year.
  • Shares Outstanding (Weighted Average) was $48.8 million for Q3 2023 at Ginkgo Bioworks Holdings, down from $1.9 billion in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $1.9 billion in Q2 2023 and bottomed at $1.6 million in Q1 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $1.2 billion, with a median of $1.3 billion recorded in 2021.
  • The sharpest move saw Shares Outstanding (Weighted Average) tumbled 99.88% in 2022, then soared 119026.78% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $1.1 billion in 2019, then rose by 10.95% to $1.3 billion in 2020, then grew by 6.67% to $1.4 billion in 2021, then plummeted by 96.91% to $42.0 million in 2022, then rose by 16.18% to $48.8 million in 2023.
  • Business Quant data shows Shares Outstanding (Weighted Average) for DNA at $48.8 million in Q3 2023, $1.9 billion in Q2 2023, and $1.9 billion in Q1 2023.